{'fraction_non_alphanumeric': 0.04197761194029851, 'fraction_numerical': 0.017723880597014924, 'mean_word_length': 5.6234567901234565, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Buprenorphine: High‐Affinity Binding to Dorsal Spinal Cord

Abstract: The binding of the mixed opiate agonist‐antagonist [3H]buprenorphine was compared with [3H]naloxone and [3H]dihydromorphine binding in membranes prepared from rat whole brain and dorsal spinal cord. Scatchard analysis of binding to whole brain yielded KD values close to 1.0 nM for all three 3H‐ligands studied, although [3H]buprenorphine labelled five times as many binding sites. [3H]Naloxone and [3H]dihydromorphine bound to dorsal spinal cord with approximately the same affinity as to whole brain, although both 3H‐ligands labelled fewer sites in the spinal cord. In contrast, Scatchard analysis of [3H]buprenorphine binding to spinal cord yielded curvilinear Scatchard plots, suggesting the presence of a very high‐affinity (KD= 0.12 nM) binding site in addition to the high‐affinity site (KD= 1.0 nM) present in the brain. Studies on the displacement of [3H]buprenorphine by opiates and d‐Ala2, Met5‐enkephalinamide supported the presence of two binding sites for this ligand in the spinal cord.